Furthermore, Severe-Death hematologic cancer patients showed a trend to increased production of IL-17A, similar to what is observed in individuals from the general population infected by SARS-CoV-2 and other SARS viruses (21). This evidence concerns the gene IL17A and hematopoietic and lymphoid cell neoplasm.